CLDN18.2-Specific CAR T-Cell Therapy Prolongs PFS in Patients with Previously Treated Advanced Gastric or Gastro-oesophageal Junction Cancer By Ogkologos - August 14, 2025 462 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CT041-ST-01 study Source RELATED ARTICLESMORE FROM AUTHOR Patient Guide on Cancer Pain Management Now Available Also in French FDA Approves Pembrolizumab with Enfortumab Vedotin-ejfv for Muscle Invasive Bladder Cancer Postneoadjuvant Trastuzumab Deruxtecan Results in Higher Likelihood of iDFS Among Patients with HER2-positive EBC with Residual Invasive Disease After Neoadjuvant Treatment MOST POPULAR “Glossy” Awareness Campaigns Weren’t Representing Her Cancer, So She Started #TrueCancerBodies April 24, 2019 Delayed irAEs Occur in a Small Subset of Patients with Melanoma,... April 1, 2021 Clinical Trials in Genitourinary Cancers: CheckMate 914, KEYNOTE-992, and KEYNOTE-991 May 20, 2021 FDA Approves Lutetium Lu 177 Vipivotide Tetraxetan for Metastatic Castration-Resistant Prostate... April 15, 2022 Load more HOT NEWS Using Artificial Intelligence to Classify Lung Cancer Types, Predict Mutations Pausing Long-Term Breast Cancer Therapy to Become Pregnant Appears to Be... Longtime NPR Reporter Shares Diagnosis to Bring More Awareness to Metastatic... Los ensayos clínicos y las personas mayores, con Dr. Enrique Soto
